Tumor-Activated Peptide Delivers Immune Drug With 1,000x Higher Concentration in Tumors
An activatable cell-penetrating peptide delivered the immune drug resiquimod to tumors at 1,000-fold higher concentration than surrounding tissue, achieving localized anti-tumor efficacy through systemic delivery.
Quick Facts
What This Study Found
ACPP-resiquimod conjugate achieved >1,000-fold greater tumor tissue concentration than surrounding normal tissue after systemic delivery. Therapeutic efficacy matched localized free resiquimod in syngeneic murine tumors. Dual enzymatic activation: MMP-2/9 cleavage + cathepsin B release.
Key Numbers
>1,000-fold tumor selectivity; MMP 2/9 activated; cathepsin B release; systemic = local efficacy
How They Did This
Preclinical study. Activatable CPP designed with MMP-2/9 cleavage site and cathepsin B-cleavable linker for resiquimod. Tissue biodistribution measured. Anti-tumor efficacy tested in syngeneic murine tumor models with systemic delivery.
Why This Research Matters
Many powerful immune drugs are too toxic for systemic use. This precision peptide delivery achieves the impossible — systemic injection with localized tumor effects — potentially making potent immune modulators safe enough for clinical cancer therapy.
The Bigger Picture
Activatable CPPs represent a breakthrough in targeted cancer therapy. By using the tumor's own enzymes to activate the delivery peptide, this approach eliminates off-target toxicity — the main barrier to many powerful immune therapies.
What This Study Doesn't Tell Us
Mouse tumor models only. MMP expression varies between human tumors. Drug payload limited to resiquimod in this study. Manufacturing complexity of peptide-drug conjugates. Long-term safety not assessed.
Questions This Raises
- ?Can this ACPP platform deliver other immune modulators or chemotherapy drugs to tumors?
- ?Would it work in human tumors with variable MMP expression?
- ?Could ACPP-drug conjugates replace intratumoral injections that currently require direct tumor access?
Trust & Context
- Key Stat:
- 1,000x tumor selectivity Activatable CPP achieved over 1,000-fold higher drug concentration in tumor tissue compared to surrounding normal tissue after systemic injection
- Evidence Grade:
- Moderate evidence: preclinical study with impressive biodistribution data and therapeutic efficacy in murine tumors. No human data.
- Study Age:
- Published 2021. Activatable CPP and peptide-drug conjugate technologies are advancing toward clinical cancer applications.
- Original Title:
- Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs.
- Published In:
- Pharmaceutics, 13(3) (2021)
- Database ID:
- RPEP-05445
Evidence Hierarchy
Frequently Asked Questions
How does the peptide know to activate only in tumors?
The activatable CPP has a "mask" that keeps it inactive. Tumors produce specific enzymes (matrix metalloproteinases) that cut off this mask, revealing the cell-penetrating portion. This only happens in tumor tissue where these enzymes are abundant, sparing normal tissue.
Why is 1,000x selectivity important?
Many cancer drugs work well against tumors but damage healthy tissue. Achieving 1,000-fold higher drug concentration in tumors versus normal tissue means the drug fights cancer effectively while minimizing side effects — potentially enabling use of drugs that are too toxic for systemic delivery.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05445APA
Hingorani, Dina V; Camargo, Maria F; Quraishi, Maryam A; Adams, Stephen R; Advani, Sunil J. (2021). Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs.. Pharmaceutics, 13(3). https://doi.org/10.3390/pharmaceutics13030365
MLA
Hingorani, Dina V, et al. "Tumor Activated Cell Penetrating Peptides to Selectively Deliver Immune Modulatory Drugs.." Pharmaceutics, 2021. https://doi.org/10.3390/pharmaceutics13030365
RethinkPeptides
RethinkPeptides Research Database. "Tumor Activated Cell Penetrating Peptides to Selectively Del..." RPEP-05445. Retrieved from https://rethinkpeptides.com/research/hingorani-2021-tumor-activated-cell-penetrating
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.